Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced a new agreement with Renaissance Lakewood LLC to advance the development of its lead therapeutic candidate intranasal foralumab.
The partnership will focus on optimizing the formulation and scaling up production of the investigational therapy, which is being developed for neurodegenerative and inflammatory diseases.
Renaissance, a Contract Development and Manufacturing Organization (CDMO) specializing in nasal drug delivery, will provide its expertise to ensure high-quality production that meets regulatory standards.
Tiziana highlighted the agreement as a key step to clinical development and potential commercialization of foralumab.
“Partnering with Renaissance is a significant milestone in our mission to bring intranasal foralumab to patients in need,” Tiziana Life Sciences CEO Ivor Elrifi said in a statement.
“Their proven track record in pharmaceutical manufacturing will be invaluable as we advance our clinical programs and prepare for potential market entry.”
Intranasal foralumab is a fully human, anti-CD3 monoclonal antibody designed to modulate the immune system by reducing neuroinflammation. The therapy has shown promise in treating conditions such as Alzheimer's disease and multiple sclerosis by activating regulatory T cells that can cross the blood-brain barrier and dampen microglial activation.